A phase 2a study of S-637880 in patients with neuropathic low back pain

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031200418

Enrollment

160

Registered

2021-03-12

Start date

2021-03-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic low back pain

Interventions

Oral administration of S-637880 or placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet the following criteria: - Patients with chronic pain located in the posterior aspect of the trunk and between the twelfth rib and the inferior end of the gluteal fold - Patients whose average daily pain intensity are 4 or higher on Visit 1 - Patients whose weekly mean of average daily pain intensity are 4 or higher and less than 10 for 7 days including Visit 2 (Day 1) on Visit 2

Exclusion criteria

Exclusion criteria: Patients who are considered to have primary pain other than low back and leg pain or patients with neuropathic pain other than low back and leg pain

Design outcomes

Primary

Measure	Time frame
Changes from the baseline to 8 weeks administration in weekly mean of maximum daily pain intensity as measured by the Numerical Rating Scale	—

Contacts

Public Contact- Corporate Communications Department

Shionogi & Co., Ltd.

shionogiclintrials-admin@shionogi.co.jp+81-6-6209-7885

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026